Founded in 2020 by immunologists Dr. Yang Liu and Dr. Pan Zheng, OncoC4 leverages deep immuno-oncology expertise to create a pipeline of innovative biologic therapies with first-in-class or best-in-class potential. The Rockville, Maryland company is advancing multiple clinical-stage candidates that target both novel and well-validated pathways across oncology and immunological disorders. Its strategy centers on rigorous global clinical development complemented by active business development to broaden therapeutic reach. Although specific revenue or patient metrics were not disclosed, the company characterizes itself as having a broad pipeline poised for growth. Proceeds from its latest financing will fund continued clinical development of these pipeline programs. Management emphasizes a commitment to delivering disruptive therapies to patients worldwide. The company’s leadership team includes Dr. Yang Liu, who serves as Chairman, CEO, and CSO.

Total raised

$50M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2025